0001735276-18-000074.txt : 20180928 0001735276-18-000074.hdr.sgml : 20180928 20180928165724 ACCESSION NUMBER: 0001735276-18-000074 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180927 FILED AS OF DATE: 20180928 DATE AS OF CHANGE: 20180928 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vaishnaw Akshay CENTRAL INDEX KEY: 0001458494 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 181094783 MAIL ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770602661 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2018-09-27 0 0001178670 ALNYLAM PHARMACEUTICALS, INC. ALNY 0001458494 Vaishnaw Akshay 300 THIRD STREET CAMBRIDGE MA 02142 0 1 0 0 President, R&D Performance Stock Option 2015 (right to buy) 88.95 2018-09-27 4 A 0 7500 0.0 A 2018-09-27 2025-12-18 Common Stock 7500 22500 D Performance Stock Option 2016 (right to buy) 42.22 2018-09-27 4 A 0 6250 0.0 A 2018-09-27 2026-12-20 Common Stock 6250 12500 D On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares. On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. By: /s/ Michael P. Mason, Attorney-in-Fact For: Akshay K. Vaishnaw 2018-09-28